Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells.The EC50 for this effect is less than 0.3ng/ml.
Product Details
Product Details
Product Specification
Species | Human |
Accession | P15018 |
Amino Acid Sequence | Ser23-Phe202 |
Expression System | E.coli |
Molecular Weight | 19-20kDa (Non-reducing) |
Purity | >95%by SDS-PAGE&RP-HPLC |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | 20mM Tris, 200mM NaCl, pH8.0 |
Reconstitution | Reconstitute at 0.5-1mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Background
Leukaemia inhibitory factor (LIF) is produced by many different cell types and has pleiotropic actions. LIF stimulates the differentiation of the macrophage cell line M1, and the proliferation of haematopoietic stem cells. In vivo, it has profound effects on haematopoiesis, particularly in combination with other cytokines such as IL-3, causing increased platelet formation. LIF allows embryonic stem cells to remain in an undifferentiated state and can maintain their proliferation in culture. LIF stimulates synthesis of acute phase proteins by liver cells, increases bone resorption, stimulates differentiation of cholinergic nerves and loss of body fat.
Picture
Picture
Bioactivity

SDS-PAGE

RP-HPLC



